Results 121 to 130 of about 30,536 (239)

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri, Negar Asadollahei, Yasamin Haghir‐Sharif‐Zamini, Homeyra Seydi, Mahsa Salehi, Mehrnaz Mesdaghi, Mustapha Najimi, Massoud Vosough   +7 more
wiley   +1 more source

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Haematologica, 2012
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.
Michael Lübbert, Björn H. Rüter, Rainer Claus, Claudia Schmoor, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Konstanze Döhner, Anne Hagemeijer, Pierre W. Wijermans, Hartmut Döhner   +18 more
doaj   +1 more source

A semantic web framework to integrate cancer omics data with biological knowledge [PDF]

, 2012
BACKGROUND: The RDF triple provides a simple linguistic means of describing limitless types of information. Triples can be flexibly combined into a unified data source we call a semantic model.
James P McCusker, Kei-Hoi Cheung, Matthew E Holford, Michael Krauthammer   +3 more
core   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, Volume 158, Issue 2, Page 342-356, 15 January 2026.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia

Frontiers in Pharmacology
BackgroundThe objective of this real-world cohort study was to evaluate the efficacy and safety of decitabine versus conventional chemotherapy in the maintenance therapy (MT) of patients with acute myeloid leukemia (AML).MethodsData were collected from ...
Zhi-Feng Wei, Zhi-Feng Wei, Jia-Qi Yan, Jia-Qi Yan, Ye-Hui Tan, Ye-Hui Tan, Hai Lin, Hai Lin, Qiu-Ju Liu, Qiu-Ju Liu, Xiao-Liang Liu, Xiao-Liang Liu, Long Su, Long Su, Su-Jun Gao, Su-Jun Gao   +15 more
doaj   +1 more source

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma

BMC Cancer, 2018
Background Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the ...
Timothy Budden, Andre van der Westhuizen, Nikola A. Bowden   +2 more
doaj   +1 more source

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer [PDF]

, 2014
PURPOSE: To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.
Azab, Mohammad, Choy, Gavin, Fang, Fang, Lyons, John, Matei, Daniela, Miller, David F. B., Munck, Joanne, Nephew, Kenneth P., Pawelczak, Katherine S., Pilrose, Jay, Tang, Jessica, Taverna, Pietro, Turchi, John J., VanderVere-Carozza, Pamela, Wagner, Michael, Wang, Yinu   +15 more
core   +1 more source

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

New lipid nanocapsules for decitabine encapsulation [PDF]

, 2016
Introduction: Currently decitabine, an antimetabolite agent is approved for acute myeloid leukemia in old patients and is administered via intra-venous (IV) route.
E. Roger, F. Lagarce, N. Lautram, T. Briot   +3 more
core  

Chromatin remodeling agents for cancer therapy [PDF]

, 2008
Alterations in chromatin structure profoundly influence gene expression during normal cellular homeostasis and malignant transformation. Methylation of cytosines within CpG islands located in promoter and proximal coding regions facilitates recruitment ...
Cinti, Caterina, Estenoz, Mariela, Giordano, Roberto, La Sala, Dario, Magnano, Anna   +4 more
core   +1 more source